Arix Bioscience

Arix Bioscience is a global venture capital firm based in London, specializing in biotechnology investments. Founded in 2016, Arix focuses on backing early-stage companies that are developing breakthrough treatments and technologies in the life sciences sector. Their investment strategy targets ventures from late pre-clinical to clinical stages, emphasizing a diversified portfolio to mitigate risks inherent in biotech investments​. The firm has built a robust portfolio that includes companies like Autolus, a developer of CAR-T cell therapies for cancer, and Disc Medicine, which focuses on treatments for hematologic diseases. Arix has also been involved in significant financing rounds, such as the $50 million Series B for Evommune and Ensoma, highlighting their role in advancing innovative biotech startups. Arix operates a permanent capital model, allowing it to support its portfolio companies through market fluctuations without being bound by strict exit timelines. This approach enables them to provide sustained support to their investments, which is critical in the high-risk, high-reward biotech sector.